Plus   Neg

Stock Alert: Adial Pharma Gains 25% On Distribution Deal With BioLab For COVID-19 Test Kits

Shares of Adial Pharmaceuticals Inc. (ADIL) jumped over 25% on Monday morning after the clinical-stage biopharmaceutical company announced a distribution deal with BioLab Sciences for a COVID-19 antibody test kits.

ADILS is currently trading at $2.1996, up $0.4596 or 26.4138%, on the Nasdaq.

Adial Pharmaceuticals said it has entered into a distribution deal with BioLab Sciences, Inc., a regenerative biotechnology company, which manufactures and sells Rapid Result COVID-19 antibody test kits.

Under the agreement, Adial has purchased Rapid Result COVID-19 antibody test kits from BioLab for use in Adial's landmark ONWARDÔ pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder.

BioLab has also granted Adial exclusive rights to sell Rapid Result COVID-19 antibody test kits to designated channel partners.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. on Friday unlocked the New York Post's Twitter account after a two-week stalemate over posting links to its reporting about Hunter Biden. Walmart has removed guns and ammunition from its store shelves in the U.S. as a precautionary measure following the unrest in Philadelphia after a Black man was fatally shot by police, according to reports. While the firearms will be available for purchase at the Walmart stores, customers will be required to specifically request for them. Regeneron Pharmaceuticals Inc. (REGN) said Friday that the independent data monitoring committee or IDMC for the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended to hold further enrollment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
Follow RTT